A
A. Pretnar-Darovec
Publications - 3
Citations - 196
A. Pretnar-Darovec is an academic researcher. The author has contributed to research in topics: Discontinuation & Randomized controlled trial. The author has an hindex of 3, co-authored 3 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Who special programme of research, development and research training in human reproduction
H.K. Toppozada,Suporn Koetsawang,V. E. Aimakhu,T. Khan,A. Pretnar-Darovec,T.K. Chatterjee,M. P. Molitor-Peffer,R. Apelo,R. Lichtenberg,P. G. Crosignani,J.C. de Souza,M. Garcia Huidubro,A.A. Haspels,J. Annus,G. Benaginao,P. Diethelm,R. Gray,P.E. Hall,S. Holck +18 more
TL;DR: All three injectable regimens compare favourably with oral contraceptives in terms of pregnancy and total continuation rates observed in clinical trial settings and for family planning programs, NET-EN (60-day) has the advantage of low pregnancy rates compared to NET- EN (84-day), and a schedule of administration that does not change.
Journal ArticleDOI
A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive efficacy and side effects
S. Said,K. Omar,Suporn Koetsawang,Orawan Kiriwat,Yuwadee Srisatayapan,A. Kazi,F. Ajmal,H.H. Wynter,A. Pretnar-Darovec,I.B. Benitez,J. R. de la Cruz,R. Apelo,László Kovács,S. Koloszar,B. Busca,P.E. Hall,David Machin,David Machin +17 more
TL;DR: Two dosages of depot-medroxyprogesterone acetate, 100 mg and 150 mg given every 90 days, were compared in two groups of women with regard to effectiveness, reported complaints and reasons for discontinuation, showing little difference in efficacy and side effects.
Journal ArticleDOI
A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction.
S. Said,K. Omar,Suporn Koetsawang,Orawan Kiriwat,Yuwadee Srisatayapan,A. Kazi,F. Ajmal,H.H. Wynter,A. Pretnar-Darovec,I.B. Benitez,J. R. de la Cruz,R. Apelo,László Kovács,S. Koloszar,Catherine d'Arcangues,B. Busca,P.E. Hall,David Machin +17 more
TL;DR: There is a high degree of consistency between the reasons given by individual women for discontinuing the contraceptive method and their vaginal bleeding pattern during the 90 days preceding discontinuations, however the data revealed large between-centre differences, both in the incidence of specific patterns, and in the identification by women of bleeding problems as reasons for discontinuation.